Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalacom combination ophthalmic solution.

Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalacom combination ophthalmic solution. - Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalacom combination ophthalmic solution

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026231

Enrollment

100

Registered

2017-02-20

Start date

2017-01-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma or ocular hypertension

Interventions

Switching from Xalacom combination ophthalmic solution to Mikeluna combination ophthalmic solution

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: glaucoma or ocular hypertension good adherence before the study initiation

Exclusion criteria

Exclusion criteria: some corneal abnormality or other diseases which may interfere with accurate IOP measurement history of glaucoma surgery contraindicated to Beta blockers

Design outcomes

Primary

Measure	Time frame
IOP reduction Adverse event	—

Countries

Japan

Contacts

Public ContactKenji Inoue

Inouye Eye Hospital Medical office

study@inouye-eye.or.jp03-3295-0911

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026